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Abstract
Background: We assessed NanoString's nCounter™ Analysis System for its ability to quantify
gene expression of forty-eight genes in a single reaction with 100 ng of total RNA or an equivalent
amount of tissue lysate. In the nCounter™ System, multiplexed gene expression target levels are
directly detected, without enzymatic reactions, via two sequence-specific probes. The individual
mRNA is captured with one mRNA target sequence-specific capture probe that is used in a post-
hybridization affinity purification procedure. The second mRNA target specific-sequence and
fluorescent-labeled colored coded probe is then used in the detection with the 3-component
complex separated on a surface via an applied electric field followed by imaging. We evaluated
reproducibility, accuracy, concordance with quantitative RT-PCR, linearity, dynamic range, and the
ability of the system to assay different inputs (matched samples of total RNA from Flash Frozen
(FF) and Formalin Fixed Paraffin Embedded Tissues (FFPET), and crude tissue lysates (CTL)).
Findings:  The nCounter™ Analysis System provided data equivalent to that produced by
Taqman®-based assays for genes expressed within the ranges of the calibration curves (above ~0.5
mRNA copies per human cell based on an assumption of 10 pg of total RNA per cell). System
response was linear over more than two orders of magnitude with typical CVs of ~6% for
concentrations above 1 fM (105 molecules per mL). Profiling the industry-standard MAQC data set
yielded correlation coefficients of >0.83 for intensity values and >0.99 for measured ratios. Ninety
percent of nCounter™ ratio measurements were within 1.27–1.33 fold changes of the Taqman®
data (0.34–0.41 in log2 scale) for FF total RNA samples.
Conclusion: The nCounter™ Analysis System generated robust data for multi-gene expression
signatures across three different sample preparation conditions.
Background
Analyses of gene expression from microarrays can be used
to define a specific set of sequences (signatures) relevant
to a particular biological phenomenon or response [1].
These signatures can comprise tens to hundreds of genes,
a range that falls between the optimal economic and logis-
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tic space for two widely-used tools for measuring gene
expression, RT-PCR and microarrays. A solution for fol-
low-up would provide cost-effective, multiplexed meas-
urements of gene expression for tens to hundreds of genes
while producing data equivalent to that generated by
microarrays and RT-PCR. This solution should also be
able to analyze input materials of clinical relevance (e.g.,
total RNA from formalin-fixed, paraffin embedded tissues
(FFPET) and crude tissue lysates (CTL)).
As part of an internally funded investigation, Merck scien-
tists tested the ability of the nCounter™ Analysis System
[2] to meet this need via an experimental design (see
Table 1) that featured both synthetic spike-in and "natu-
ral" total RNA for a set of 48 probes. Microarray Quality
Consortium (MAQC) [3] total RNAs, total RNA from
matched flash frozen (FF) and formalin fixed, paraffin
embedded tissues, and CTL prepared from the same FF tis-
sue were used as source materials for the assay. The work
was contracted to Nanostring and the data analyzed at
Merck.
Methods
List of transcripts for the nCounter™ assay
The gene list for nCounter™ probes consisted of 14 human
genes differentially regulated in our xenograft system, 25
human genes differentially regulated among the MAQC
samples, and 9 sequences corresponding to synthetic tran-
scripts used historically at Rosetta Inpharmatics as spike-
ins for quality control (http://www.Agilent.com, Two-
Color Microarray Spike-In Kit, part # 5188–5279, [4],
Table 2). In addition, the nCounter™ Analysis System rou-
tinely includes spike-ins (cocktail #3 or #4,)[2]. These
nCounter™ assay spike-in controls can be used for calibra-
tion and quality control purposes. For this work, the
nCounter™ spike-in controls spanned 2.5 logs in concen-
tration.
Samples
Samples (see Table 1) for the assay came from two
sources: 1) EBC-1 lung cancer cell line xenograft tissues
treated with vehicle or varying amounts of a compound;
and 2) MAQC samples obtained from Ambion (Human
Brain) and Stratagene (Universal Human Reference). Pro-
portional mixes (25%:75% and 75%:25% UHR to Brain)
were created. Crude tissue lysates (CTLs) were made by
homogenizing 50–100 mg of FF xenograft tissues in 1 mL
of Qiagen buffer RLT http://www.Qiagen.com and snap
freezing a 100 μL aliquot (1/10th of total volume). Total
RNA was purified from the remaining lysate using a Tri-
zol-based protocol http://www.invitrogen.com. We iso-
lated RNA from FFPE EBC1 xenografts using the Ambion
RecoverAll protocol http://www.ambion.com. In all sam-
ples, one or the other set of Rosetta spike-ins were added
to provide a measure of ratio accuracy. Samples were
blinded before assaying at Nanostring Technologies,
where the samples were processed to generate raw data
(i.e. counts/gene). nCounter™ assay spike-ins control
mixes #3 or #4 were added at random to each of the
blinded RNA samples on the day the assay was performed.
The nCounter™ System assay
We performed the nCounter™ assay using 100 ng of total
RNA or 2 μL of tissue lysate per replicate. Each assay was
performed in triplicate to improve precision of the meas-
urements. Details can be found in [2].
RT-PCR
Fourteen genes were assayed via a Taqman® quantitative
RT-PCR protocol according to manufacturer's specifica-
tions using Applied Biosystem's High Capacity cDNA
Reverse Transcription Kit (part # 4374967) and Taqman®
Universal PCR Master Mix (part # 4364340). Taqman
reporter probes were used (see Table 1 for a list of specific
ABI assay identifiers). An aliquot of 400 ng of total RNA
was reverse-transcribed and 1/80th of the reaction used for
each replicate for each probe. The reaction volume for
each replicate was 10 μL, with 0.5 μL of the Taqman 20×
gene expression assay, 1 μL of sample, 5 μL of 2× Master
Mix and 3.5 μL dH2O. All samples were assayed in quad-
ruplicate for each probe according to Rosetta internal
SOPs. Samples were run on an ABI 7900 HT system using
the recommended ABI cycling protocol http://
www3.appliedbiosystems.com/AB_Home/index.htm. See
Table 2 for the specific Taqman® identifiers for the 14
probes used.
Table 1: Experimental samples
Sample Type # of Samples Replicated? Synthetic spike-ins added? Total # assayed
MAQC samples (Brain, UHR, and 25%:75% proportional mixes of each) 4 Yes (1×) Yes (?) 8
Tissue Lysates 10 No Yes 10
Flash frozen total RNA (4 xenografts at 4 different dosage conditions) 16 Yes (1×) Yes 32
FFPET total RNA 8 No Yes 8BMC Research Notes 2009, 2:80 http://www.biomedcentral.com/1756-0500/2/80
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Table 2: Gene list for nCounter™ probe synthesis.
Gene/Gene Symbol Representative Transcript/Transcript ID Taqman probe ID (if used)
ASPA NM_000049.2
BCL6 NM_001706 Hs00153368_m1
C11orf58 NM_014267.3
CCNG2 NM_004354 Hs00171119_m1
CDH1 NM_004360.2
CHGB NM_001819.1
CUGBP1 NM_006560.2|NM_198700.1|NM_001025596.1 Hs00198069_m1
DNAJB9 NM_012328.1
DYNLL1 NM_001037494.1|NM_001037495.1|NM_003746.2
H6PD NM_004285.3 Hs00188728_m1
HBEGF NM_001945.1
HIST1H1D NM_005320.2
HKR2 NM_181846.1 Hs00419189_m1
ICAM1 NM_000201.1
IRS2 NM_003749 Hs00275843_s1
ITM2B NM_021999.2
LDHA NM_005566.1
LGI1 NM_005097.1
MDS032 NM_018467.2
MLLT7 NM_005938 Hs00172973_m1
MMP2 NM_004530.2
MS4A6A NM_152852.1|NM_022349.2|NM_152851.1 Hs00223521_m1
MXD4 NM_006454 Hs00170799_m1
MYC NM_002467 Hs00153408_m1
NARG1 NM_057175 Hs00228208_m1
NIP7 NM_016101 Hs00602949_g1
NR0B2 NM_021969.1
NTS NM_006183.3BMC Research Notes 2009, 2:80 http://www.biomedcentral.com/1756-0500/2/80
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Data analysis
Eleven positive control nCounter™ spike-ins (spanning
from 0.27 fM to 55 fM) were used to create the calibration
curve for each nCounter™ array. Nine negative control
spike-ins were used to assess the level of background (typ-
ically on the order of 10 counts). Mean of the negative
controls was deducted from all other transcripts in the
same assay prior to logarithmic transformation (log base
2). We used a standard linear regression model to find the
least square fit of logarithm-transformed concentration
on the logarithm-transformed number of molecules
above background to generate the equation for the rest of
the transcripts in the same assay. Each nCounter™ assay
result was converted to an equivalent concentration using
the assay standard curve. Use of the standard curve allows
absolute measurements to be assigned to nCounter™
counts as needed.
To deduce the precision of the nCounter™ assay itself, we
mean centered the data in log2 scale, resulting in a correc-
tion of approximately 1.08 fold. To achieve specified pre-
cision, NanoString recommends running each sample (by
experiment) in triplicate. To mimic a typical experiment,
therefore, we averaged triplicate assays for Rosetta spike-
ins as well. Standard deviations of resulting mean values
were used to calculate CVs.
PPARA NM_001001928.2|NM_005036.4
RNF10 NM_014868.3
SEPT2 NM_001008491.1|NM_001008492.1|NM_006155.1|NM_004404.3
SFRS10 NM_004593.1
SHCBP1 NM_024745.2
SLC25A32 NM_030780 Hs00229219_m1
TAF1A NM_005681 Hs00375858_m1
TFRC NM_003234.1
THBS1 NM_003246.2
TMSL8 NM_021992.2
TP53 NM_000546.2
r60_1 NA
r60_3 NA
r60_a104 NA
r60_a107 NA
r60_a135 NA
r60_a20 NA
r60_a22 NA
r60_a97 NA
r60_n11 NA
r60_n9 NA
Table 2: Gene list for nCounter™ probe synthesis. (Continued)BMC Research Notes 2009, 2:80 http://www.biomedcentral.com/1756-0500/2/80
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To generate across-multiple-samples, gene-by-gene equiv-
alency plots, both Taqman® and nCounter™ data were nor-
malized to CUGBP1 as a reference gene for the xenograft
samples. Originally four reference genes were identified
from previous experiments as not varying significantly
across our experimental conditions and were planned to
be used as references in aggregate. However, three of the
four did not reliably give signals above the lower limit of
our standard curve and so were not used. This led us to
deviate from generally accepted practice in which more
than one reference gene is used to normalize data.
In the MAQC analysis, although the published Taqman®
data were normalized to POLR2A, the nCounter™ normal-
ization did not utilize any reference genes. This is because
POLR2A was not one of the genes present in our genelist
and so was unavailable as a common control. As a result
of this approach, Taqman®  data were normalized to
mRNA amount, while nCounter™ normalization relied on
the same amount of total RNA (100 ng) in each sample.
This distinction is important because the MAQC study
showed that UHR has 1.5-fold higher mRNA content than
Brain (3% vs. 2%). To compensate for different mRNA
content, 0.585 Ct, 0.46 Ct and 0.17 Ct were deducted
from all genes of 0% Brain/100% UHR; 25% Brain/75%
UHR; and 75% Brian/25% UHR samples, respectively.
For performance evaluations, a comparison was done for
each possible pair of samples because we did not wish to
artificially bias our data by arbitrarily assigning one sam-
ple as the "standard" to which other replicates would be
compared. In these cases, we normalized to the mean of
log intensity of the subset of genes in the corresponding
sample for which measurements were above 0.27 fM in
both samples of the pair. The same subset of genes was
used to normalize Taqman®, using their mean Ct.
Assessment of the Spike-in performance and of the MAQC
samples can be found in Additional File 1, Additional File
2, Additional File 3, and Additional File 4, and in Tables 3
and 4. Data from the analysis can be found in Additional
File 5.
Results and discussion
Analysis of Xenograft-derived Samples
The sample set comprised four treatment conditions with
four mouse xenografts per condition for a total of 16 sam-
ples. The 16 tissue samples were split and preserved by
three methods (FF, FFPET, and CTL in Qiagen buffer RLT);
total RNA was isolated from FF and FFPET for RT-PCR
analysis. Fourteen genes were chosen for Taqman® com-
parison using samples that were either vehicle treated or
treated with the highest level of compound. Ten genes
Table 3: Expected and back-calculated (observed) concentrations in fmoles of Nanostring spike-in mixes 3 and 4, including %CV and 
%Bias. 
Nanostring spike-in Mix #3 Nanostring spike-in Mix #4
Spike Name Expected Observed StdDwev CV, % Bias, % Expected Observed StdDev CV, % Bias, %
S23 50 61.45 3.48 5.7 22.9 50 59.45 3.63 6.1 18.9
S14 5 3.36 0.28 8.5 32.9 5 3.24 0.31 9.5 35.2
S19 0.5 0.42 0.07 17.2 16.5 0.5 0.45 0.08 17.3 10.6
S8 5 3.19 0.24 7.5 36.2 15 9.94 0.62 6.3 33.7
S13 15 10.74 0.48 4.5 28.4 5 3.08 0.31 10.0 38.5
S22 5 4.72 0.30 6.3 5.5 50 56.19 3.77 6.7 12.4
S7 50 53.23 2.67 5.0 6.5 5 4.36 0.30 7.0 12.9
S17 1.5 2.41 0.25 10.4 60.8 4.5 7.96 0.75 9.4 76.9
S3 4.5 5.4 0.33 6.0 19.9 1.5 1.62 0.19 11.8 7.8
S6 0.25 0.31 0.07 21.8 23.3 0.75 1.02 0.13 12.8 35.7
S4 0.75 1.06 0.13 12.1 41.5 0.25 0.38 0.07 17.7 50.4
Calculations based on all replicates.BMC Research Notes 2009, 2:80 http://www.biomedcentral.com/1756-0500/2/80
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were expected to change either up or down, and four ref-
erence genes were expected to remain constant. The genes
chosen for Taqman® and Nanostring comparisons were
picked based on internal Merck criteria. The differential
expression in a previous microarray study of these sam-
ples showed relatively modest fold changes (~2 fold) at
the highest compound treatment level used for this study
(data for other, intermediate treatment levels is not
shown).
A comparison of the compound and vehicle intensities
between nCounter™ and Taqman® is shown in Figures 1, 2
and 3 for nine of the ten genes expected to change
between treatments. Reference genes are not shown and
one of the ten differentially expressed genes was not
present at a sufficiently high level for accurate assessment.
Figure 1 corresponds to FF tissue; Figure 2 to FFPET; and
Figure 3 to CTL. In Figures 1, 2 and 3 only those points
with expression levels within the calibration range are
shown. The reference gene CUGBP1 was used to calculate
the delta-delta CT for all genes.
As with the MAQC data, these sample sets show generally
good agreement between the two platforms. The one out-
lier is NARG1 (top right graph in each Figure), which was
consistently discordant in all Taqman® to nCounter™
Table 4: Expected and observed concentrations for Rosetta spike-ins 11 and 12, including %CV and %Bias.
Rosetta spike-in #11
Transcript name Intended conc, AU Best Fit Expected Observed StdDev CV, % Bias, %
r60_a20:50:rp 100 32.09 28.62 1.47 5.2 10.8
r60_a22_rp 10 3.21 4.71 0.28 5.9 46.9
r60_a104_rp 10 3.21 2.62 0.14 5.2 18.5
r60_1_rp 10 3.21 4.29 0.26 6.1 33.6
r60_a107_rp 30 9.63 10.56 0.70 6.6 9.7
r60_3_rp 3 0.96 1.02 0.09 9.1 6.1
r60_a135_rp 9 2.89 3.13 0.16 5.0 8.3
r60_a97_rp 0.5 0.16 0.14 0.03 21.8 15.5
r60_n11:30:rp 1.5 0.48 0.34 0.07 21.3 30.1
Rosetta spike-in #12
r60_a20:50:rp 100 44.18 37.56 2.25 6.0 15.0
r60_a22_rp 100 44.18 81.54 5.51 6.8 84.5
r60_a104_rp 30 13.25 12.16 0.70 5.8 8.2
r60_1_rp 10 4.42 5.85 0.30 5.1 32.3
r60_a107_rp 10 4.42 4.49 0.36 8.0 1.6
r60_3_rp 9 3.98 4.28 0.25 5.8 7.7
r60_a135_rp 3 1.33 1.30 0.08 6.2 1.6
r60_a97_rp 1.5 0.66 0.61 0.07 11.3 7.9
r60_n11:30:rp 0.5 0.22 0.12 0.04 29.7 43.6
Calculations based on a per-sample basis.BMC Research Notes 2009, 2:80 http://www.biomedcentral.com/1756-0500/2/80
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comparisons. Since the region of NARG1 assayed by the
Taqman® probe is at the junction between exons 1 and 2
and the region selected for the nCounter™ probe is close
to the 3' end of the transcript, the two systems may be cap-
turing valid but different transcript behavior of this gene.
It should be noted that variability of measurements in the
CTL samples (as represented by the error bars) was higher
than for the other two sample types.
The FF and lysate data have a high degree of correlation,
suggesting minor loss of data quality by using CTLs rather
than purified total RNA. Taken together, the data in Fig-
ures 1, 2 and 3 suggest that the nCounter™ assay can be
used to generate data from clinical samples with degraded
RNA (FFPET, see Additional File 6 for representative qual-
ity) or from lysate preparations. It should be pointed out,
however, that the FFPET model used (xenograft tissue) is
not a perfect match for typical clinical samples and that
not all degrees of degraded RNA will be amenable to this
system
Performance metrics
To assess bias or compression in derived ratios, we plotted
differences in ratios between nCounter™ and Taqman®
versus average of ratios reported by both platforms (Figure
4). The scatter around the abscissa axis (y = 0) of differ-
ences suggests no bias in the measurement of ratios by
nCounter™ relative to Taqman®, while the random scatter
Comparison of intensities derived from Taqman® and  nCounter™ for FF-derived total RNA Figure 1
Comparison of intensities derived from Taqman® 
and nCounter™ for FF-derived total RNA. The line in 
each case represents a slope of 1. Blue and black dots repre-
sent the two replicate measurements for each mouse sample. 
Only data points within the calibration curve are presented 
in these graphs. Units for the x-axis are delta CTs using 
CUGBP1 to normalize; units for the y-axis are log2 ratios of 
nCounter™ counts for a given gene and CUGPB1. Error 
bars represent standard deviations.
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Comparison of intensities derived from Taqman® on FF total  RNA and nCounter™ on FFPET-derived total RNA Figure 2
Comparison of intensities derived from Taqman® on 
FF total RNA and nCounter™ on FFPET-derived 
total RNA. The line in each case represents a slope of 1. 
Only data points within the calibration curve are presented 
in these graphs. Units for the x-axis are delta CTs using 
CUGBP1 to normalize; units for the y-axis are log2 ratios of 
nCounter™ counts for a given gene and CUGPB1. Error 
bars represent standard deviations.
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Comparison of intensities derived from Taqman® on FF total  RNA and nCounter™ on tissue lysates Figure 3
Comparison of intensities derived from Taqman® on 
FF total RNA and nCounter™ on tissue lysates. The 
line in each case represents a slope of 1. Only data points 
within the calibration curve are presented in these graphs. 
Units for the x-axis are delta CTs using CUGBP1 to normal-
ize; units for the y-axis are log2 ratios of nCounter™ counts 
for a given gene and CUGPB1. Error bars represent standard 
deviations.
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across  degrees of differential expression (along the x-
axis)implies no compression of ratios across ratio values.
Figure 5 displays a set of cumulative distribution function
(CDF) curves for ratios reported by the nCounter™ assay
for the MAQC and the three xenograft datasets (FF, FFPET
and CTL) versus the Taqman®-derived ratios from the FF
samples. The absence of ratio compression simplifies the
subsequent analysis: since the magnitude of the ratio does
not affect the concordance between two platforms by this
method, we can combine all measurements together and
determine how many measurements were off and by how
much. Rather than depend solely on one references gene,
we performed a comparison of all possible sample pairs;
systematic shifts affecting all genes in each comparison
were thereby attributed to the difference in total mass and
subtracted out. As expected, ratios measured by
nCounter™ and Taqman® were similar for MAQC and FF
xenograft samples. The MAQC samples showed slightly
less deviation between Taqman® and the nCounter™ Sys-
tem, which may reflect the controlled nature of the sam-
ple set and the smaller fraction of very-low intensity genes
(see Table 3 for CV dependence on transcripts abun-
dance). Overall the differences are small–for example,
90% of all nCounter™ measurements were within 1.27
and 1.33 fold changes of the Taqman® calculated ratio for
the MAQC and cell line FF data, respectively. Interestingly,
nCounter™ data from the CTL samples more closely mir-
rored the Taqman® data than did the FFPET total RNA
data. However, even ratios reported by nCounter™ FFPET
samples are close to Taqman® ratios obtained for FF sam-
ples: 90% of ratios were within 1.55 fold.
Our impetus to assess the nCounter™ Analysis System was
driven by its relative simplicity (that is, no need for ampli-
fication steps), its multiplexed format, and its potential to
measure gene expression in samples from pre-clinical and
clinical settings (e.g, fine-needle biopsies in lysate buffers,
and FFPET materials). Our results confirmed the system
has potential for pre-clinical and clinical measurements of
multiple gene signatures in settings where the initial tissue
collection would be conducive to FFPET or CTL prepara-
tions.
This platform could be used to fill an important and grow-
ing gap in drug development research. Microarray experi-
ments routinely are used in basic research but often
identify too many genes to allow higher-throughput
downstream use of those signatures for screening or read-
outs. By allowing the cost effective and accurate measure-
ment of expression of tens of genes from clinical samples,
the nCounter™ system could facilitate translation of
multi-gene expression based biomarkers into the clinic.
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Additional file 1
Performance of Nanostring spike-ins. Nanostring spike-ins span a 
reported range from 0.25 fM to 50 fM. All samples were assayed in trip-
licate; data are broken down by replicate. nCounter™ spike-ins consisted 
of two parallel sets of the same RNAs made into two different cocktails 
(cocktails #3 and #4). Some RNAs are set at different concentrations 
between these cocktails while others are at the same concentration (Table 
3).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
0500-2-80-S1.doc]
Additional file 2
Performance of Rosetta spike-ins. The Rosetta spike-ins were originally 
constructed to measure dynamic range, ratio fidelity, and hybridization 
quality of an in-house, two-color microarray system [4]. Data from the 
nCounter™ spike-in controls were used to derive the precision profile and 
to provide a calibration curve for quantitation of other RNA transcripts. 
Spike-ins curves showed good linearity and reproducibility, and good con-
servation of relative measurements. Overall, the precision of the platform 
for the Rosetta Spike-ins had CVs of approximately 6%, except for concen-
trations below 1.5 fM (CVs were 10–30%). Error bars represent standard 
deviations.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
0500-2-80-S2.doc]
Additional file 3
Comparison of intensity values derived from Taqman® (x-axis) and 
Nanostring (y-axis) for each of the four MAQC samples (UHR, 25% 
Brain/75% UHR, 75% Brain/25% UHR, and Brain). Markers in red 
represent genes that were outside of the calibration curve. Pair-wise 
nCounter™ to Taqman® comparisons of measured expression levels of 
genes on a per sample basis showed correlation coefficients ranging from 
0.835 to 0.886. Error bars represent standard deviations.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
0500-2-80-S3.doc]
Additional file 4
Comparison of calculated log2 ratios for Brain vs UHR for Nanostring 
and Taqman®. Transcripts that were outside the calibration curve are 
shown in red and are labeled with their lowest measured concentration in 
either Brain or UHR (in fM). In the comparison of ratios, data for 
nCounter™ and Taqman® were first corrected for the known differences in 
mRNA content between Brain and UHR (2% to 3%). Additional File 4 
shows the fit of the ratio comparisons to the line y = x for samples whose 
intensity falls within the standard curve (blue squares in Additional File 
4), R = 0.995, demonstrating good linear agreement between Taqman® 
and nCounter™ ratio measurements.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
0500-2-80-S4.doc]
Additional file 5
Data from Nanostring nCounter experiment. This spreadsheet contains 
the raw nCounter™ data, the Taqman® data used for comparisons, and the 
normalized and averaged nCounter™ data.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
0500-2-80-S5.xls]
Additional file 6
Representative Bioanalyzer traces from FFPE-derived RNA. These 
traces demonstrate the degree of RNA degradation assayed by the 
nCounter™ system in our experiments.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-
0500-2-80-S6.doc]